Quest Diagnostics CEO sells 10,000 shares

Quest Diagnostics CEO and President J. E. Davis reported an open-market sale of 10,000 shares of Common Stock on June 1, 2026 at a price of $194.14 per share.

Accepted by SEC EDGAR 06/02/2026 - 06:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Quest Diagnostics CEO and President J. E. Davis reported an open-market sale of 10,000 shares of Common Stock on June 1, 2026 at a price of $194.14 per share.

After this transaction, Davis directly holds 132,423 shares of Quest Diagnostics Common Stock. The sale was carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person, indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Davis J. E.

Role CEO and President

Sold 10,000 shs ($1.94M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$194.14	$1.94M

Holdings After Transaction: Common Stock — 132,423 shares (Direct)

Footnotes (1)

1. F1. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Key Figures

Shares sold: 10,000 shares Sale price: $194.14 per share Shares held after sale: 132,423 shares

3 metrics

Shares sold 10,000 shares Open-market sale on June 1, 2026

Sale price $194.14 per share Price for Common Stock sold

Shares held after sale 132,423 shares Direct ownership after transaction

Key Terms

Rule 10b5-1 sales plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 sales plan regulatory

"The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) report for J. E. Davis?

Quest Diagnostics reported that CEO and President J. E. Davis sold 10,000 shares of Common Stock in an open-market transaction at $194.14 per share. The sale was executed on June 1, 2026 under a pre-arranged Rule 10b5-1 sales plan.

How many Quest Diagnostics (DGX) shares does J. E. Davis hold after this sale?

After the reported transaction, J. E. Davis directly holds 132,423 shares of Quest Diagnostics Common Stock. This figure reflects his position following the 10,000-share open-market sale disclosed in the Form 4 filing for June 1, 2026.

Was the Quest Diagnostics (DGX) insider sale by J. E. Davis pre-planned?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 sales plan adopted by J. E. Davis. Such plans schedule trades in advance, meaning the timing of this 10,000-share sale was predetermined rather than a spontaneous market decision.

What price did J. E. Davis receive per Quest Diagnostics (DGX) share sold?

The Form 4 shows that J. E. Davis sold 10,000 shares of Quest Diagnostics Common Stock at $194.14 per share. This reported price represents the transaction price per share for the open-market sale executed on June 1, 2026.

Does the Quest Diagnostics (DGX) Form 4 include any option exercises or derivative transactions?

No derivative transactions are listed in this Form 4 excerpt. The filing reports a single non-derivative transaction: an open-market sale of 10,000 shares of Quest Diagnostics Common Stock by J. E. Davis, with no option exercises or conversions shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis J. E.

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		10,000	D	$194.14	132,423	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for James E. Davis	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)